Tunicamycin — An inhibitor of yeast glycoprotein synthesis
References (15)
- et al.
Biochem. Biophys. Res. Commun
(1969) - et al.
Biochim. Biophys. Acta
(1958) - et al.
FEBS Letters
(1970) - et al.
J. Biol. Chem
(1968) - et al.
J. Antibiotics
(1971) - et al.
J. Antibiotics
(1972) - et al.
J. Antibiotics
(1971)
There are more references available in the full text version of this article.
Cited by (193)
Nucleoside-derived inhibitors of MraY: Medicinal chemistry with natural products
2023, Annual Reports in Medicinal ChemistrySmall molecule inhibitors of mammalian glycosylation
2022, Matrix Biology PlusIdentification and characterization of enzymes involved in the biosynthesis of pyrimidine nucleoside antibiotics
2021, Natural Product ReportsMetabolic labeling of glycans with isotopic glucose for quantitative glycomics in yeast
2021, Analytical BiochemistryCitation Excerpt :We also assess the robustness of MILPIG using a panel of normal (12C) and isotope-labeled (13C) glycan mixtures from differentially labeled yeast cells. Finally, we examined the difference in N-linked glycans expression under in normal and tunicamycin-treated cells using MILPIG approach [37,38]. Collectively, our results corroborate that MILPIG has an excellent potential for relative glycomics to study glycan changes in physiological conditions in cell culture.
Copyright © 1974 Published by Elsevier Inc.